Editorial: Benefits and risks of agonist triggering strategies
Saved in:
| Main Author: | Jan Tesarik |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1538412/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
by: Yinghao Sun, et al.
Published: (2020-07-01) -
Comparison of clinical outcomes between flexible antagonist protocol and long luteal phase protocol in patients with normal ovarian reserve function: a prospective cohort study
by: Ying Tian, et al.
Published: (2025-08-01) -
Ovarian sensitivity index affects clinical pregnancy and live birth rates in gonadotropin-releasing hormone agonist and antagonist in vitro fertilization cycles
by: Chao Chin Hsu, et al.
Published: (2024-12-01) -
Comparison of hCG Versus Gonadotropin-Releasing Hormone Agonist to Induce Oocyte Maturation in Assisted Reproductive Technology Cycles: A Retrospective Cohort Study
by: Gulay Beydilli Nacak, et al.
Published: (2021-08-01) -
Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding
by: Danielle A. Aase, et al.
Published: (2025-01-01)